跳至主要内容
临床试验/NCT05732272
NCT05732272招募中3 期

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

University of Kansas Medical Center1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2023年2月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
500
试验地点
1
主要终点
Verified abstinence at Month 6

研究概览

简要总结

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

详细描述

The primary objective of this study is to evaluate extended use of bupropion with the goal of enhancing abstinence in African American daily smokers, including the full spectrum of light, moderate, and heavy smokers. A two-arm, randomized design will be used to evaluate the efficacy of extended (6 months) bupropion treatment compared to standard (7 weeks) bupropion treatment. Baseline randomization stratified by gender and cpd (≤10, >10cpd) will assign participants (N=500) to receive extended treatment (EXT; 24 weeks of bupropion, n=250) or standard treatment (ST; 7 weeks of bupropion, n=250). All participants will receive culturally-relevant, individualized smoking cessation counseling, including support for medication adherence, and will be followed through Month 12.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • African American
  • age >18 years
  • interested in quitting
  • smoked >1 cpd for >1 years
  • smoked on >25 days in the past month
  • willing to take 6 months of study medication and complete all visits
  • have a home address and functioning telephone number

排除标准

  • Consistent with contraindications for bupropion:
  • use of psychoactive medications
  • history of alcohol or substance abuse within the past year
  • binge drinking (>5 drinks on one occasion) >2 times in the past month
  • history of seizures or head trauma; history of bulimia or anorexia nervosa
  • pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding
  • myocardial infarction in the past 2 months
  • reported use of opiates, cocaine, or stimulants
  • unstable diabetes
  • bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded.
  • use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days
  • planning to move from the Kansas City area in the next year
  • other smoker in household enrolled in the study.

研究组 & 干预措施

Standard Treatment

Active Comparator

250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

干预措施: Bupropion (Drug)

Extended Treatment

Active Comparator

250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

干预措施: Bupropion (Drug)

结局指标

主要结局

Verified abstinence at Month 6

时间窗: Month 6

Participants receiving extended bupropion treatment will have significantly higher Month 6 verified point-prevalence abstinence than participants receiving standard bupropion treatment.

次要结局

  • Adherence to medication(Week 4)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验